GlassScriptPhysician profile
Mary Patterson
NPI 1770230963
$722.22
in general payments reported to CMS, 2019-2025
15 companies · $400 in 2025
The $400 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $17.77 · 2023: $41.89 · 2024: $263 · 2025: $400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $704.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $704.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $195.75 | 2024-2025 | Zoryve |
| Lilly USA, LLC | $110.37 | 2024-2025 | Jardiance, Mounjaro |
| Astellas Pharma US INC | $105.27 | 2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $72.05 | 2022-2024 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $38.11 | 2025 | |
| Sanofi-Aventis U.S. LLC | $31.14 | 2024 | |
| Pfizer INC. | $28.40 | 2024 | |
| Exact Sciences Corporation | $23.20 | 2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $20.15 | 2024 | |
| Alk-Abello, INC | $19.70 | 2024 | Odactra, Ragwitek, Grastek |
| Otsuka America Pharmaceutical, INC. | $17.26 | 2025 | Rexulti |
| Photonicare INC | $17.00 | 2024 | Otosight Middle Ear Scope |
| Dexcom, INC. | $15.18 | 2024 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $15.16 | 2023 | Ozempic, Rybelsus |
| Amgen INC. | $13.48 | 2024 | Repatha, Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Patterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.